Testing LY3439539 for early-stage Alzheimer's disease
Part of Brain & nervous system, Mental health clinical trials.
This study tests an experimental drug called LY3439539 in people with early-stage Alzheimer's disease. The drug is designed to target protein changes in the brain that may slow memory loss and cognitive decline.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have had gradual memory problems for at least 6 months that match an Alzheimer's diagnosis
- Your memory and thinking score (Mini Mental State Examination) is between 16 and 24
- You have specific protein markers (pTau) in your blood that match the study criteria
- Your body mass index is between 17 and 32
- You have one or two study partners (family or close friends) who see you at least 10 hours per week
- You can see, hear, and read well enough to complete study visits and procedures
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new medicine called LY4006895 in two groups: healthy volunteers and people with early symptomatic Alzheimer's disease. It aims to see how the drug works in the body and if it might help memory and thinking.
This study tests several new experimental medications that target amyloid plaques, the protein clumps linked to Alzheimer's disease. It aims to find out if these treatments are safe and well-tolerated in people with early-stage Alzheimer's and in healthy volunteers.
This study tests an experimental drug called LY4405094 in healthy people and in people with Alzheimer's disease. It aims to see if the drug is safe and how the body handles it, which could lead to new treatments for Alzheimer's.
This study tests an experimental drug (LY3954068) for people with early Alzheimer's disease. It aims to see if the drug is safe and may slow memory loss. You'll need a PET scan to measure tau protein in the brain and have a study partner who can help attend appointments.
This trial tests a new drug called CM383 in people with mild cognitive impairment or mild Alzheimer's disease. The goal is to see if it can help slow down memory loss.
This study tests an investigational drug called BEY2153 for people with early Alzheimer's disease. It aims to see if the drug is safe and can help slow memory decline.
Hear when a new Alzheimer Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.